Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma.
about
Methotrexate for high-grade osteosarcoma in children and young adultsOsteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted TherapiesMYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedemaThe tumor-suppressive microRNA-135b targets c-myc in osteoscarcoma.Influence of reduced folate carrier and dihydrofolate reductase genes on methotrexate-induced cytotoxicity.The molecular pathogenesis of osteosarcoma: a reviewBET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cellsExpression and significance of Kruppel-like factor 6 gene in osteosarcoma.Genetically engineered mouse models and human osteosarcoma.Loss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis.Emerging drugs for high-grade osteosarcoma.How genetic variation affects patient response and outcome to therapy for psoriasis.Orthopaedic research in italy: state of the art.Pivotal regulatory network and genes in osteosarcomaPharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.The pharmacogenomics of osteosarcoma.ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy.Over-expression of c-Myc oncoprotein in oral squamous cell carcinoma in the South Indian population.c-MYC-induced genomic instability.Identification and analysis of key genes in osteosarcoma using bioinformatics.
P2860
Q24234472-C0AE5FF5-C8B6-444B-8583-B9CE55CFE30AQ26745742-F80D6EF9-DC1B-41B8-B3CE-E4AFEB977C27Q33556211-706DB7F0-4F1B-4F8C-B73A-8722078DD84DQ33905746-48E39C5E-E592-4D10-BB9E-10F2D9573DDAQ34193075-ACA5E0FA-EF87-449F-9DC3-201FBC5DC8B0Q34629074-52051CAC-F14C-4720-AB0D-368AB3B50BABQ35574955-2C33A938-4CB4-4FBE-9973-D760225A6A21Q36285123-2F4E6CC5-0EB0-45B2-B7D5-8593D0E62F4FQ36468644-984A21A5-29C6-4C37-8969-C515D071C346Q36750689-AC60F1A8-6B07-4F13-BAB4-EB10B07C3FC2Q37778400-2D8708D2-9F8B-4F53-8716-8043B2B7BBD5Q37803415-C794714C-5051-4787-9B3D-47F32FAA5BD4Q37888852-95024A7F-5A01-4D42-8741-45F46FEC8A66Q38488094-1B7AD72F-AE46-4EAE-9505-9CC394B3734CQ38809116-B0FCDE52-6AC5-4FCF-B49E-A50A0AC0D0A7Q38848413-0AB15932-6C63-4F3E-8D68-7BD135305D53Q38850586-4CBEFE4A-BD89-46E2-BA2B-FA8E4DA0346AQ39369837-66DAFD64-614E-4233-AE6A-42AE962F6BC7Q42127661-C7539E4F-E57D-41DB-83E9-AE26AF0299A4Q49788841-3E53201B-0C5D-46C6-9A51-363B562B837B
P2860
Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Clinical impact of the methotr ...... R) in high-grade osteosarcoma.
@en
Clinical impact of the methotr ...... YC and dihydrofolate reductase
@nl
type
label
Clinical impact of the methotr ...... R) in high-grade osteosarcoma.
@en
Clinical impact of the methotr ...... YC and dihydrofolate reductase
@nl
prefLabel
Clinical impact of the methotr ...... R) in high-grade osteosarcoma.
@en
Clinical impact of the methotr ...... YC and dihydrofolate reductase
@nl
P2093
P50
P356
P1433
P1476
Clinical impact of the methotr ...... FR) in high-grade osteosarcoma
@en
P2093
F Michelacci
M Alberghini
M C Manara
P304
P356
10.1093/ANNONC/MDN148
P577
2008-04-02T00:00:00Z